trial · primary record
CS1-CAR T Therapy
Recurrent Plasma Cell Myeloma
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2027-08-13 |
| Primary endpoint | Incidence of dose-limiting toxicity (DLT) and all other toxicities |
| Registry ID | NCT03710421 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:36.299Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03710421
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.